Core Laboratories N.V. (CLB) Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. lifted its position in shares of Core Laboratories N.V. (NYSE:CLB) by 27.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 814,142 shares of the oil and gas company’s stock after purchasing an additional 177,077 shares during the quarter. JPMorgan Chase & Co. owned 1.84% of Core Laboratories N.V. worth $82,449,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of CLB. ProShare Advisors LLC raised its position in shares of Core Laboratories N.V. by 8.5% during the first quarter. ProShare Advisors LLC now owns 3,802 shares of the oil and gas company’s stock worth $439,000 after purchasing an additional 297 shares during the period. Sumitomo Mitsui Asset Management Company LTD raised its position in shares of Core Laboratories N.V. by 21.5% during the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 3,684 shares of the oil and gas company’s stock worth $425,000 after purchasing an additional 653 shares during the period. Oregon Public Employees Retirement Fund acquired a new position in shares of Core Laboratories N.V. during the first quarter worth approximately $1,055,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Core Laboratories N.V. by 0.9% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,667 shares of the oil and gas company’s stock worth $770,000 after purchasing an additional 59 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its position in shares of Core Laboratories N.V. by 11.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 2,834 shares of the oil and gas company’s stock worth $327,000 after purchasing an additional 300 shares during the period.
A number of equities analysts have recently weighed in on CLB shares. ValuEngine lowered Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Royal Bank Of Canada lowered their target price on Core Laboratories N.V. from $115.00 to $112.00 and set an “outperform” rating on the stock in a research report on Thursday. Zacks Investment Research lowered Core Laboratories N.V. from a “buy” rating to a “hold” rating in a research report on Friday, June 23rd. Credit Suisse Group raised Core Laboratories N.V. from a “neutral” rating to an “outperform” rating and set a $110.00 target price on the stock in a research report on Thursday, August 24th. They noted that the move was a valuation call. Finally, Cowen and Company reaffirmed a “hold” rating and set a $100.00 target price on shares of Core Laboratories N.V. in a research report on Friday, September 1st. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $113.58.
Shares of Core Laboratories N.V. (NYSE:CLB) opened at 91.18 on Monday. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of 55.94 and a beta of 1.60. Core Laboratories N.V. has a 52-week low of $86.55 and a 52-week high of $125.83. The company has a 50-day moving average price of $94.24 and a 200-day moving average price of $105.02.
Core Laboratories N.V. (NYSE:CLB) last released its earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The business had revenue of $163.90 million for the quarter, compared to the consensus estimate of $168.23 million. During the same period in the previous year, the company posted $0.35 earnings per share. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, equities analysts anticipate that Core Laboratories N.V. will post $2.04 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, August 14th. Shareholders of record on Monday, July 17th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.41%. The ex-dividend date was Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is 134.15%.
TRADEMARK VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/11/core-laboratories-n-v-clb-shares-bought-by-jpmorgan-chase-co.html.
Core Laboratories N.V. Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Stock Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related stocks with our FREE daily email newsletter.